Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope against deadly mold infections: generic drug shows promise

NCT ID NCT07239765

Disease control Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a generic version of an antifungal drug called Amphotericin B Cholesteryl Sulfate Complex (ABCD) in 67 adults with invasive mold disease, a serious infection. The goal was to see if the drug is safe and works well. Participants received the drug through an IV, and researchers tracked side effects and how many completed treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Amphotericin B Cholesteryl Sulfate Complex (ABCD)
What this could lead to
If successful, this could provide a new generic treatment option for serious mold infections, potentially improving access and outcomes.
What could go wrong
This is a completed Phase 3 trial with only 67 participants, so results may not apply to all patients. Amphotericin B can cause kidney problems and infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

67 people

The number who actually took part.

Started

Jul 2021

Finished

Apr 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years of age; * Participant had a diagnosis of proven/probable invasive mold disease (IMD) as determined according to European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC-MSG) criteria (2019 version) or proven/probable talaromycosis as determined according to diagnostic criteria for endemic mycosis. Exclusion Criteria: * Allergy to amphotericin B or cholesteryl sulfate complex; * Mycoses only involved skin above fascia; * Expected survival less than 2 months; * Pregnant or breast-feeding; * Non-negative result on HIV antibody

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Invasive mold disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

penicilliosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Invasive mold disease

Contacts and locations

Locations

  • The First Affiliated Hospital Of Guangzhou Medical University

    Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.